Ritter, Thomas K. Ph.D.

Current Employment Position(s)

Associate

Languages

• English
• German

Lawyer Overview

Tom Ritter advises IP clients in all areas of chemistry and related fields, in particular polymers and life sciences. Tom's experience includes drafting and prosecuting German, European, and international (PCT) patent applications, as well as representing clients in subsequent opposition proceedings. He also provides patentability, validity, freedom-to-operate, and infringement opinions and is involved in nullity and infringement proceedings.

Tom studied chemistry and biochemistry in Germany and in the United States. For his Ph.D. thesis, he explored different routes towards the inhibition of bacterial transglycosylase, synthesizing a new class of thiazolines as well as a library of vancomycin analogs. In this context, he participated in the development of a programmable one-pot method for the synthesis of oligosaccharides. Tom has been working in intellectual property law since 2003. Before joining Jones Day, he was an associate in the firm of Vossius & Partner in Munich.

Areas of Practice

• Intellectual Property
• Patent Prosecution
• Patent Litigation
• Chemicals
• Life Sciences
• Pharmaceuticals

Representative Cases

• Actimis develops patent portfolio for CRTH2 and CCR3 modulators , (2009)
• BioSphere develops global patent portfolio related to polyvinyl alcohol microspheres , (2009)
• Celgene establishes global patent portfolio for small molecule pharmaceuticals , (2009)
• Chemetall successfully defends European patent relating to organometallic compounds
• Oxy establishes global patent portfolio for resorcinol resins , (2009)
• PTC Therapeutics builds patent portfolio for small molecule technology , (2009)
• Sachtleben Chemie prevails in first round of opposition proceedings against LWB Refractories over patent relating to refractory moulds and compounds , (2009)
• Sepracor develops patent portfolio directed to isomers and metabolites, including CLARINEX® and ALLEGRA® , (2009)
• Signal Pharmaceuticals maintains patent portfolio for small molecule kinase inhibitors , (2009)
• Solyndra develops global patent portfolio for solar cell technology , (2009)
• Sunesis Pharmaceuticals builds patent portfolio for small molecule oncological drugs , (2009)
• Versitech builds global patent portfolio for electronic displays and other technologies , (2009)

West Practice Categories

Copyrights, Intellectual Property Law, International Intellectual Property, Patent Litigation, Patents, Technology Licensing, Trade Dress, Trade Secrets, Trademarks

Education

• Scripps Research Institute
• U Konstanz - Germany
• U of Oregon

Published Works

• Acceptor Specificity and Inhibition of the Bacterial Cell Wall Glycosyltransferase MurG, ChemBioChem 4 (2003) 603-609, 2003
• A Programmable One-Pot Oligosaccharide Synthesis for Diversifying the Sugar Domains of Natural Products: A Case Study of Vancomycin, Angewandte Chemie, Int. Ed. Engl. 42 (2003) 4657-4660, 2003
• Carbohydrate-Based Drug Discovery in the Battle Against Bacterial Infections; New Opportunities Arising from Programmed One-Pot Oligosaccharide Synthesis, Carbohydrate-Based Drug Discovery, Editor: Chi-Huey Wong, 2003, Wiley-VCH, Weinheim, 2003
• Synthesis of N-Acetylglucosamine Thiazoline/Lipid II Hybrids, Tetrahedron Letters 42 (2001) 615-618, 2001
• Carbohydrate-based Antibiotics: A New Approach to Tackling the Problem of Antibiotic Resistance, Angewandte Chemie, Int. Ed. Engl. 40 (2001) 3508-3533, 2001

Address

Prinzregentenstr. 11
80538 Munich, Federal Republic of Germany

Phones

49.89.20.60.42.200 (Business Phone)

Faxes

49.89.20.60.42.293 (Business Fax)

Emails

Contact Us (Business Email)

Websites

http://www.jonesday.com